Ventas, Inc. research snapshot
VTR AI stock analysis currently reads Ventas as a leading healthcare REIT tied to the longevity economy, with roughly 1,450 properties, more than 900 senior housing communities, outpatient medical and research assets, and triple-net healthcare properties. The August 2026 setup follows Q2 2026 results released July 30, 2026, when Ventas beat consensus, raised 2026 normalized FFO guidance to $3.85 to $3.90 per share, lifted its 2026 investment target to $4.5 billion, and cut net debt to Further Adjusted EBITDA to 4.7x. The investment case is still not a simple buy signal because the stock trades near 24x the midpoint of 2026 normalized FFO guidance, GAAP earnings remain low relative to price, the company is issuing a large amount of equity to fund growth, and the business remains exposed to interest rates, senior housing labor costs, operator execution, and healthcare real estate cycles.
Current price
$93.51 close on July 31, 2026
Market cap
$48.29 billion verified market cap
AI score
68 / 100
Rating
High-quality healthcare REIT with accelerating senior housing growth, raised 2026 guidance, improving leverage, and a valuation that already prices in much of the recovery
Trend status
Uptrend above the 50-day and 200-day moving averages, but consolidating below the $101.60 52-week high after a pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Ventas owns roughly 1,450 healthcare properties, including more than 900 senior housing communities, outpatient medical and research assets, and triple-net healthcare real estate that benefit from aging demographics, healthcare demand, and property-level operating improvement. | High |
| Moat | Scale, location quality, operator relationships, healthcare real estate expertise, data-driven Ventas OI initiatives, and access to public capital support the moat, but REIT assets are capital intensive and rate sensitive. | Medium-high |
| Management | Debra Cafaro has led a long-running healthcare REIT platform and delivered Q2 2026 normalized FFO of $0.97, raised 2026 normalized FFO guidance to $3.85 to $3.90, raised the 2026 investment target to $4.5 billion, and improved net debt to Further Adjusted EBITDA to 4.7x. | Medium-high |
| Financial trend | Q2 2026 revenue rose to $1.73 billion and H1 2026 revenue reached $3.39 billion. FY2025 revenue was about $5.8 billion and FY2025 net income attributable to common stockholders was roughly $251 million. | High |
| Valuation | At $93.51, VTR screens near 170x trailing EPS, 129.8x forward EPS, 7.5x sales, 3.27x book value, 12.21x PEG, and about 24x the midpoint of 2026 normalized FFO guidance, with a 2.22% dividend yield. | High |
| Technical trend | The stock trades above its 50-day moving average near $89.02 and 200-day moving average near $82.84 but below the $101.60 52-week high, with RSI near 50.13 after a pullback. | Medium |
| Risk level | Main risks are a stretched valuation, equity dilution from about $4.2 billion of equity capital raised, higher rates, senior housing labor inflation, weaker occupancy, operator or tenant stress, healthcare reimbursement pressure, and paying too much for recovery growth. | Medium-high |
| AI confidence | Descriptive confidence is high because Q2 2026 results and third-party data align. Return confidence is lower because REIT multiples can reset quickly when rates or capital-market conditions change. | High data confidence |
| Investment certainty | VTR is a strong healthcare REIT platform, but the current price needs continued SHOP growth, successful $4.5 billion of planned investments, stable rates, and limited dilution to justify the rerating. | Medium |
VTR AI stock forecast
The VTR AI stock forecast is scenario-based because Ventas depends on senior housing occupancy, RevPOR, labor costs, cap rates, interest rates, equity funding, leverage, and FFO growth. At the July 31, 2026 close of $93.51, the stock trades near 24x the midpoint of the raised 2026 normalized FFO guidance of $3.85 to $3.90 per share. The scenario ranges below are stress-test bands built on FFO growth and multiple changes, not target promises.
$110 to $135 before dividends
More likely if SHOP same-store cash NOI keeps growing near double digits, the $4.5 billion investment target closes accretively, 2026 normalized FFO moves above $4.00 per share, leverage keeps improving, and long rates stay stable.
$85 to $105 before dividends
More likely if VTR delivers the raised guidance of $3.85 to $3.90, senior housing growth offsets higher funding costs, investments are accretive, and the market values the company near current healthcare REIT multiples without a major rate shock.
$60 to $75 before dividends
More likely if rates rise, further equity issuance becomes dilutive, labor costs squeeze SHOP margins, tenant or operator stress returns, occupancy growth slows, or investors reprice VTR closer to lower-growth REIT multiples.
VTR AI technical analysis
VTR AI technical analysis is constructive but consolidating as of the August 2, 2026 data cutoff. StockAnalysis showed a July 31, 2026 close of $93.51 and a 52-week range of $65.82 to $101.60. The stock trades above its 50-day moving average near $89.02 and 200-day moving average near $82.84, with RSI near 50.13, meaning the uptrend is intact but momentum has normalized after the run to the 52-week high.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $93.51 close on July 31, 2026 | StockAnalysis listed a July 31, 2026 close of $93.51, with after-hours near $94.38. |
| Immediate support | $90 to $92 | This range brackets the recent consolidation zone just above the 50-day moving average, where buyers stepped back in after the pullback from the high. |
| Trend support | $88 to $90 | This range sits near the 50-day moving average reported around $89.02 and is the first trend-health check zone. |
| Long-term support | $82 to $85 | This range brackets the 200-day moving average near $82.84 and is a deeper trend-risk review zone. |
| Near resistance | $99.68 to $101.60 | The analyst average target near $99.68 and the 52-week high near $101.60 create the first resistance band. |
| Upper resistance | $105 to $115 | This is a scenario zone, not a target promise. It likely requires stronger FFO guidance, steady rates, and continued SHOP acceleration. |
| Moving averages | 50-day near $89.02, 200-day near $82.84 | Trading above both averages supports the current uptrend. A close below the 50-day average would reduce trend confidence. |
| Momentum | RSI near 50.13 | Momentum has normalized to a neutral reading after the pullback from the high, so the next directional signal depends on whether price holds support or regains the high. |
| Volume | July 31 volume near 4.30 million shares | StockAnalysis reported July 31 volume near 4.30 million shares versus a 20-day average near 3.19 million, which marks participation around the earnings reaction. |
| Volatility | Watch late October 2026 earnings | The next earnings release, rate moves, senior housing occupancy, acquisition funding, and FFO guidance are likely volatility drivers. |
| Invalidation | Close below $89, then below $82.84 | A sustained break below the 50-day zone weakens the trend. A break below the 200-day zone would challenge the larger uptrend. |
VTR AI trading strategy
The VTR AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with senior housing NOI, occupancy, RevPOR, labor costs, interest rates, net debt to EBITDA, dividend coverage, acquisition funding, and FFO guidance.
Watch for VTR to hold the $90 to $92 support area and keep trading above the 50-day average while Q3 results confirm SHOP growth, FFO guidance, liquidity, and leverage improvement.
A close below $89 should reduce trend confidence, especially if management signals weaker occupancy, higher labor costs, less accretive acquisitions, or higher funding costs.
If VTR pulls back toward the $82 to $85 long-term support zone without a break in senior housing demand or balance-sheet stress, compare the lower price with normalized FFO, dividend coverage, and asset value.
Do not treat a pullback as attractive if higher rates compress REIT valuations, SHOP margins deteriorate, tenants weaken, or further equity issuance is needed at unfavorable prices.
Track SHOP same-store cash NOI, occupancy, RevPOR, labor expense, 2026 normalized FFO per share, net debt to Further Adjusted EBITDA, liquidity, the pace of the $4.5 billion investment program, dividend growth, and 10-year Treasury yields.
Position sizing should reflect that Ventas is a high-quality but rate-sensitive REIT trading at a premium valuation, not a guaranteed income stock or a precise AI price prediction.
Investment research summary
Customers and tenants pay Ventas because seniors, healthcare providers, universities, research users, and operators need specialized real estate in attractive markets. The business converts healthcare property ownership, operating partnerships, and capital allocation into rent, resident fees, NOI, FFO, and dividends.
Ventas has scale, roughly 1,450 properties, more than 900 senior housing communities, outpatient medical and research assets, operator relationships, healthcare real estate expertise, data-driven operating insights, and access to public capital. The moat is meaningful, but it can narrow if rates rise, operators struggle, or replacement capital becomes expensive.
The thesis fails if the market overpays for a cyclical senior housing recovery, labor costs offset occupancy gains, the large equity raise dilutes holders, higher rates pressure cap rates, or tenant and operator stress damages cash flows.
Debra Cafaro has built one of the larger healthcare REIT platforms and is now executing senior housing growth, raising the 2026 investment target to $4.5 billion, improving leverage to 4.7x, and increasing dividend payout. The current test is disciplined capital allocation after a strong stock rerating and heavy equity issuance.
Aging demographics, with baby boomers beginning to turn 80, and historically low new senior housing supply support a multiyear growth runway. The offset is that real estate returns still depend on rates, labor, construction supply, reimbursement, operator health, and capital markets.
At $93.51, near 24x the midpoint of 2026 normalized FFO guidance, VTR prices in a large portion of the recovery. Margin of safety improves if normalized FFO grows above guidance or if the stock pulls back while SHOP growth, leverage, liquidity, and dividend coverage remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VTR quote reference | $93.51 close on July 31, 2026 | StockAnalysis VTR overview | August 2, 2026 |
| Market capitalization verification | $48.29 billion reported and $48.29 billion calculated from $93.51 x 516.39 million shares | StockAnalysis VTR overview and statistics | August 2, 2026 |
| Shares outstanding | 516.39 million shares outstanding, up 10.07% year over year | StockAnalysis VTR statistics | August 2, 2026 |
| Q2 2026 revenue | $1.73 billion total revenue for the quarter ended June 30, 2026, versus $1.42 billion in Q2 2025 | Ventas Q2 2026 results | August 2, 2026 |
| Q2 2026 earnings | $70.6 million net income attributable to common stockholders ($0.14 per share), $0.99 Nareit FFO per share, and $0.97 normalized FFO per share | Ventas Q2 2026 results | August 2, 2026 |
| Q2 2026 operating drivers | SHOP same-store cash NOI increased about 16.3%, total same-store cash NOI increased about 10.3%, SHOP same-store average occupancy rose 300 basis points, and RevPOR grew 5% | Ventas Q2 2026 results | August 2, 2026 |
| Q2 2026 balance sheet and liquidity | $199.0 million cash, $12.69 billion debt, $4.9 billion liquidity, and 4.7x net debt to Further Adjusted EBITDA | Ventas Q2 2026 results | August 2, 2026 |
| 2026 guidance, updated July 29, 2026 | Attributable net income per share guidance of $0.58 to $0.63, Nareit FFO per share of $3.76 to $3.81, and normalized FFO per share of $3.85 to $3.90 | Ventas Q2 2026 results | August 2, 2026 |
| FY2025 results | FY2025 revenue of about $5.8 billion and FY2025 net income attributable to common stockholders of roughly $251 million | StockAnalysis VTR financials | August 2, 2026 |
| Technical and valuation snapshot | 170.46 PE, 129.84 forward PE, 7.52 PS, 3.27 PB, 12.21 PEG, 2.22% dividend yield, 50-day moving average near $89.02, 200-day moving average near $82.84, and RSI near 50.13 | StockAnalysis VTR statistics | August 2, 2026 |
This VTR AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of August 2, 2026, and can be wrong if rates, senior housing demand, labor costs, operator performance, capital markets, or REIT valuation multiples change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
